

# EXHIBIT A

During this unprecedented time, Teva remains operational and continues to manufacture our products throughout the world.

Teva's COVID-19 Response

**AJOVY**<sup>®</sup>  
(fremanezumab-vfrm)  
injection 225 mg/1.5 mL

[Important Safety Information](#) | [Prescribing Information](#) | [Stay Connected](#) | [Visit HCP Site](#)



[ABOUT](#)

[TAKING  
AJOVY](#)

[RESOURCES](#)

[PATIENT  
STORIES](#)

[SAVINGS  
OFFER](#)

[STAY  
CONNECTED](#)



**YOU HAVE ENOUGH GOING ON**  
Wouldn't you rather do it with less migraine?

How could AJOVY reduce your migraine days?  
[SEE CLINICAL TRIAL RESULTS](#)

Which dosing option may be right for you?  
[EXPLORE YOUR OPTIONS](#)

### IMPORTANT SAFETY INFORMATION

Do not use AJOVY if you are allergic to AJOVY or any of the ingredients in AJOVY.


AJOVY may cause allergic reactions, including itching, rash, and hives that can happen within hours and up to 1 month

### APPROVED USE

AJOVY is a prescription medicine used for the preventive treatment of migraine in adults.

Please see Patient Information Leaflet within the full [Prescribing Information](#).






A promotional banner with a white background and a colorful border. On the left is a dark blue square icon containing a white dollar sign. To the right, the text reads 'Activate or get your savings offer.' Below this is a dark blue button with the text 'START SAVING TODAY' in white.

A testimonial banner. On the left is a photograph of a woman with short brown hair, smiling. Below her photo is the text 'CHER' in large white letters and 'from High Point, NC' in smaller white letters. To the right of the photo is a white text box with a blue border containing the quote: '“With fewer migraine days, I can make plans and actually stick to them.”' Below the quote is a dark blue button with the text 'SEE CHER'S STORY' in white.

### IMPORTANT SAFETY INFORMATION

Do not use AJOVY if you are allergic to AJOVY or any of the ingredients in AJOVY.

AJOVY may cause allergic reactions, including itching, rash, and hives that can happen within hours and up to 1 month after receiving AJOVY. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: swelling of your face, mouth, tongue, throat, or if you have trouble breathing. Talk to your doctor about stopping AJOVY if you have an allergic reaction.



## IMPORTANT SAFETY INFORMATION

Do not use AJOVY if you are allergic to AJOVY or any of the ingredients in AJOVY.

AJOVY may cause allergic reactions, including itching, rash, and hives that can happen within hours and up to 1 month after receiving AJOVY. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: swelling of your face, mouth, tongue, throat, or if you have trouble breathing. Talk to your doctor about stopping AJOVY if you have an allergic reaction.

Tell your healthcare provider about all the medicines you take, and if you are pregnant, planning to become pregnant, or are breastfeeding.

Common side effects of AJOVY include injection site reactions.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of AJOVY. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at 1-800-FDA-1088.


## APPROVED USE

AJOVY is a prescription medicine used for the preventive treatment of migraine in adults.

Please see Patient Information Leaflet within the full [Prescribing Information](#).

[^](#)  
back  
to top

[Legal Notice](#) | [Privacy Notice](#) | [Site Map](#)

© 2021 Teva Pharmaceuticals USA, Inc.  
FRE-43269 March 2021  
 This site is intended for US consumers only.

## Trademark/Service Mark Statement of Use (15 U.S.C. Section 1051(d))

**The table below presents the data as entered.**

Input Field	Entered
<b>SERIAL NUMBER</b>	87237174
<b>LAW OFFICE ASSIGNED</b>	LAW OFFICE 122
<b>EXTENSION OF USE</b>	NO
<b>MARK SECTION</b>	
<b>MARK</b>	<a href="https://tmng-al.uspto.gov/resting2/api/img/87237174/large">https://tmng-al.uspto.gov/resting2/api/img/87237174/large</a>
<b>LITERAL ELEMENT</b>	AJOVY
<b>STANDARD CHARACTERS</b>	YES
<b>USPTO-GENERATED IMAGE</b>	YES
<b>MARK STATEMENT</b>	The mark consists of standard characters, without claim to any particular font style, size or color.
<b>OWNER SECTION (current)</b>	
<b>NAME</b>	Teva Pharmaceutical Industries Limited
<b>INTERNAL ADDRESS</b>	Science Based Industries Campus
<b>STREET</b>	Har Hotzvim, P.O. Box 1142
<b>CITY</b>	Jerusalem
<b>ZIP/POSTAL CODE</b>	91010
<b>COUNTRY</b>	Israel
<b>PHONE</b>	215-293-6406
<b>FAX</b>	215-293-7200
<b>EMAIL</b>	XXXX
<b>AUTHORIZED TO COMMUNICATE VIA E-MAIL</b>	Yes
<b>OWNER SECTION (proposed)</b>	
<b>NAME</b>	Teva Pharmaceutical Industries Limited
<b>INTERNAL ADDRESS</b>	Science Based Industries Campus
<b>STREET</b>	Har Hotzvim, P.O. Box 1142
<b>CITY</b>	Jerusalem
<b>ZIP/POSTAL CODE</b>	91010
<b>COUNTRY</b>	Israel
<b>PHONE</b>	215-293-6509
<b>FAX</b>	215-293-7200

EMAIL	XXXX
AUTHORIZED TO COMMUNICATE VIA E-MAIL	Yes
<b>GOODS AND/OR SERVICES SECTION</b>	
INTERNATIONAL CLASS	005
CURRENT IDENTIFICATION	Pharmaceutical preparations for the treatment of migraines
GOODS OR SERVICES	KEEP ALL LISTED
FIRST USE ANYWHERE DATE	09/19/2018
FIRST USE IN COMMERCE DATE	09/19/2018
SPECIMEN FILE NAME(S)	<a href="#">\\TICRS\EXPORT17\IMAGEOUT 17\872\371\87237174\xml15\SOU0002.JPG</a>
SPECIMEN DESCRIPTION	Photo of the product
REQUEST TO DIVIDE	NO
<b>PAYMENT SECTION</b>	
NUMBER OF CLASSES IN USE	1
SUBTOTAL AMOUNT [ALLEGATION OF USE FEE]	100
TOTAL AMOUNT	100
<b>SIGNATURE SECTION</b>	
DECLARATION SIGNATURE	/laurencerickles/
SIGNATORY'S NAME	Laurence Rickles
SIGNATORY'S POSITION	Attorney of record, NY bar member
DATE SIGNED	09/27/2018
SIGNATORY'S PHONE NUMBER	215-293-6509
<b>FILING INFORMATION</b>	
SUBMIT DATE	Thu Sep 27 12:29:06 EDT 2018
TEAS STAMP	USPTO/SOU-XXX.XXX.XXX.XX- 20180927122906982928-8723 7174-61090b2a9b03dbe57591 978ca5f2a933c68cbbbab1e7d 5b527f6cde919d973813-DA-1 3551-20180927105934662210

## Trademark/Service Mark Statement of Use (15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

**MARK:** AJOVY(Standard Characters, see <https://tmng-al.uspto.gov/resting2/api/img/87237174/large>)

**SERIAL NUMBER:** 87237174

The applicant, Teva Pharmaceutical Industries Limited, having an address of

Science Based Industries Campus

Har Hotzvim, P.O. Box 1142

Jerusalem, 91010

Israel

215-293-6509

215-293-7200

XXXX (authorized)

is submitting the following allegation of use information:

For International Class 005:

Current identification: Pharmaceutical preparations for the treatment of migraines

The mark is in use in commerce on or in connection with all of the goods/services, or to indicate membership in the collective organization listed in the application or Notice of Allowance or as subsequently modified for this specific class.

The mark was first used by the applicant, or the applicant's related company, licensee, or predecessor in interest at least as early as 09/19/2018, and first used in commerce at least as early as 09/19/2018, and is now in use in such commerce. The applicant is submitting one specimen for the class showing the mark as used in commerce on or in connection with any item in the class, consisting of a(n) Photo of the product.

[Specimen File 1](#)

The applicant is not filing a Request to Divide with this Allegation of Use form.

A fee payment in the amount of \$100 will be submitted with the form, representing payment for the allegation of use for 1 class.

### Declaration

- The signatory believes that the applicant is the owner of the mark sought to be registered.  
**For a trademark or service mark application**, the mark is in use in commerce on or in connection with all the goods/services in the application or notice of allowance, or as subsequently modified.  
**For a collective trademark, collective service mark, collective membership mark application**, the applicant is exercising legitimate control over the use of the mark in commerce by members on or in connection with all the goods/services/collective membership organization in the application or notice of allowance, or as subsequently modified.  
**For a certification mark application**, the applicant is exercising legitimate control over the use of the mark in commerce by authorized users on or in connection with the all goods/services in the application or notice of allowance, or as subsequently modified, and the applicant is not engaged in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant.
- The specimen(s) shows the mark as used on or in connection with the goods/services/collective membership organization in commerce.
- To the best of the signatory's knowledge and belief, no other persons, except, if applicable, authorized users, members, and/or concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
- To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the

allegations and other factual contentions made above have evidentiary support.

- The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Signature: /laurencerickles/ Date Signed: 09/27/2018  
Signatory's Name: Laurence Rickles  
Signatory's Position: Attorney of record, NY bar member  
Signatory's Phone: 215-293-6509

RAM Sale Number: 87237174  
RAM Accounting Date: 09/27/2018

Serial Number: 87237174  
Internet Transmission Date: Thu Sep 27 12:29:06 EDT 2018  
TEAS Stamp: USPTO/SOU-XXX.XXX.XXX.XX-201809271229069  
82928-87237174-61090b2a9b03dbe57591978ca  
5f2a933c68cbbbab1e7d5b527f6cdc919d973813  
-DA-13551-20180927105934662210



NDC 51759-204-10

Rx only

**AJOVY**<sup>™</sup>  
(fremanezumab-vfrm)  
injection

**FOR SUBCUTANEOUS USE ONLY**  
One single-dose prefilled syringe

225 mg/1.5 mL

Store in refrigerator at 36°F to 46°F (2° to 8°C) in the original carton to protect from light. DO NOT FREEZE. DO NOT SHAKE. If needed, AJOVY may be kept at room temperature up to 77°F (25°C) for 24 hours. Once stored at room temperature, do not place back in the refrigerator. Discard after 24 hours.

OPEN HERE



teva

**FEE RECORD SHEET**

**Serial Number:** 87237174



**RAM Sale Number:** 87237174

**Total Fees:** \$100

**RAM Accounting Date:** 20180927

<u>Transaction</u>	<u>Fee Code</u>	<u>Transaction Date</u>	<u>Fee per Class</u>	<u>Number of Classes</u>	<u>Total Fee</u>
Statement of Use (SOU)	7003	20180927	\$100	1	\$100

**Transaction Date:** 20180927



# EXHIBIT B



## Learn more about DESCOVY®

FOR HEALTHCARE PROFESSIONALS  
[DESCOVY for PrEP](#) | [DESCOVY for HIV-1 Treatment](#)

### To Prevent HIV

**DESCOVY for PrEP®** (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex.

**DESCOVY for PrEP is not for everyone:**

- It is not for use in people assigned female at birth who are at risk of getting HIV from vaginal sex, because its effectiveness has not been studied.
- You must be HIV-negative before and while taking DESCOVY for PrEP.

Talk to a healthcare provider about your risk for HIV and if DESCOVY for PrEP may be an option for you.

[Important Safety Information](#) [Important Facts](#)

### To Treat HIV

**DESCOVY for HIV-1 treatment is a prescription medicine that is used together with other HIV-1 medicines to treat HIV-1** in people who weigh at least 77 lbs (35kg). DESCOVY combines 2 medicines into 1 pill taken once a day. Because DESCOVY by itself is not a complete treatment for HIV-1, it must be used together with other HIV-1 medicines.

**DESCOVY does not cure HIV-1 infection or AIDS.** HIV-1 is the virus that causes AIDS.

[Important Safety Information](#) [Important Facts](#)

Ask a healthcare provider if DESCOVY is right for you.

### IMPORTANT SAFETY INFORMATION FOR DESCOVY FOR PrEP

What is the most important information I should know about DESCOVY for PrEP?

Before and while taking DESCOVY for PrEP:

- You must be HIV-negative before you start and while

### IMPORTANT SAFETY INFORMATION FOR DESCOVY FOR HIV-1 TREATMENT

What is the most important information I should know about DESCOVY?

DESCOVY may cause serious side effects:

- Worsening of hepatitis B (HBV) infection. Your

- **You must be HIV-negative before you start and while taking DESCOVY for PrEP.** You must get tested for HIV-1 immediately before and at least every 3 months while taking DESCOVY. If you think you were exposed to HIV-1, tell your healthcare provider right away. They may want to do more tests to confirm that you are still HIV-negative.
- **Many HIV-1 tests can miss HIV-1 infection in a person who has recently become infected.** Tell your healthcare provider if you had a flu-like illness within the last month before starting or while taking DESCOVY. Symptoms of new HIV-1 infection include tiredness, fever, joint or muscle aches, headache, sore throat, vomiting, diarrhea, rash, night sweats, and/or enlarged lymph nodes in the neck or groin.
- **DESCOVY by itself is not a complete treatment for HIV-1.** Do not take DESCOVY for PrEP unless you are confirmed to be HIV-1 negative.
- **DESCOVY does not prevent other sexually transmitted infections (STIs).** Practice safer sex by using a latex or polyurethane condom to reduce the risk of getting STIs.
- **To further help reduce your risk of getting HIV-1:**
  - Do not miss any doses of DESCOVY. Missing doses may increase your risk of getting HIV-1.
  - Know your HIV status and the HIV status of your partners. If your partner is living with HIV, your risk of getting HIV is lower if your partner consistently takes HIV treatment every day.
  - Get tested for other STIs. Some STIs make it easier for HIV-1 to infect you.
  - Talk to your healthcare provider about all the ways to help reduce HIV risk.

#### ■ DESCOVY can cause serious side effects:

- **Worsening of hepatitis B (HBV) infection.** Your healthcare provider will test you for HBV. If you have HBV and stop taking DESCOVY, your HBV may suddenly get worse. Do not stop taking DESCOVY without first talking to your healthcare provider, as they will need to check your health or give you HBV medicine.

- **Worsening of hepatitis B (HBV) infection.** Your healthcare provider will test you for HBV. If you have both HIV-1 and HBV and stop taking DESCOVY, your HBV may suddenly get worse. Do not stop taking DESCOVY without first talking to your healthcare provider, as they will need to monitor your health or give you HBV medicine.

#### ■ What are the other possible side effects of DESCOVY?

##### Serious side effects of DESCOVY may also include:

- **Changes in your immune system.** Your immune system may get stronger and begin to fight infections. Tell your healthcare provider if you have any new symptoms after you start taking DESCOVY.
- **Kidney problems, including kidney failure.** Your healthcare provider should do blood and urine tests to check your kidneys. Your healthcare provider may tell you to stop taking DESCOVY if you develop new or worse kidney problems.
- **Too much lactic acid in your blood (lactic acidosis),** which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
- **Severe liver problems,** which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark "tea-colored" urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

The most common side effect of DESCOVY is nausea. Tell your healthcare provider if you have any side effects that bother you or don't go away.

#### ■ What should I tell my healthcare provider before taking DESCOVY?

**Do not take DESCOVY for PrEP if you:**

- **Already have HIV-1 or if you do not know your HIV-1 status.** If you have HIV-1, you need to take other medicines with DESCOVY to treat HIV-1. If you have HIV-1 and take only DESCOVY, your HIV-1 may become harder to treat now and in the future.

**What are the other possible side effects of DESCOVY for PrEP?**

**Serious side effects of DESCOVY may also include:**

- **Kidney problems, including kidney failure.** Your healthcare provider should do blood and urine tests to check your kidneys before and during treatment with DESCOVY. If you develop kidney problems, your healthcare provider may tell you to stop taking DESCOVY.
- **Too much lactic acid in your blood (lactic acidosis),** which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
- **Severe liver problems,** which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark "tea-colored" urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

**Common side effects** in people taking DESCOVY for PrEP are diarrhea, nausea, headache, fatigue, and stomach pain. Tell your healthcare provider if you have any side effects that bother you or do not go away.

**What should I tell my healthcare provider before taking DESCOVY for PrEP?**

- **All your health problems.** Be sure to tell your healthcare provider if you have or have had any kidney or liver problems, including hepatitis.

provider if you have or have had any kidney or liver problems, including hepatitis virus infection.

- **All the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. Other medicines may affect how DESCOVY works. Keep a list of all your medicines and show it to your healthcare provider and pharmacist. Ask your healthcare provider if it is safe to take DESCOVY with all of your other medicines.
- **If you are pregnant** or plan to become pregnant. It is not known if DESCOVY can harm your unborn baby. Tell your healthcare provider if you become pregnant while taking DESCOVY.
- **If you are breastfeeding** (nursing) or plan to breastfeed. Do not breastfeed. HIV-1 can be passed to the baby in breast milk.

**You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.**

**What is DESCOVY for HIV-1 treatment?**

DESCOVY for HIV-1 treatment is a prescription medicine that is used together with other HIV-1 medicines to treat HIV-1 in people who weigh at least 77 lbs (35kg). DESCOVY combines 2 medicines into 1 pill taken once a day. Because DESCOVY by itself is not a complete treatment for HIV-1, it must be used together with other HIV-1 medicines.

**DESCOVY does not cure HIV-1 or AIDS.** HIV-1 is the virus that causes AIDS.

**Please see Important Facts about DESCOVY for HIV-1 treatment, including important warnings.**

provider if you have or have had any kidney or liver problems, including hepatitis.

- **All the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. DESCOVY may interact with other medicines. Keep a list of all your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

**You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.**

### What is DESCOVY for PrEP?

**DESCOVY for PrEP** (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex.

**DESCOVY for PrEP is not for everyone:**

- It is not for use in people assigned female at birth who are at risk of getting HIV from vaginal sex, because its effectiveness has not been studied.
- You must be HIV-negative before and while taking DESCOVY for PrEP.

Talk to a healthcare provider about your risk for HIV and if DESCOVY for PrEP may be an option for you.

**Please see Important Facts about DESCOVY for PrEP, including important warnings.**



[Global Corporate Web Site](#) | [Terms of Use](#) | [Privacy Policy](#) | [Contact Us](#)

DESCOVY, the DESCOVY Logo, DESCOVY FOR PrEP, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies.

© 2020 Gilead Sciences, Inc. All rights reserved. DVYC0157 02/20



## Combined Declaration of Use and Incontestability under Sections 8 & 15

The table below presents the data as entered.

Input Field	Entered
<b>REGISTRATION NUMBER</b>	4876632
<b>REGISTRATION DATE</b>	12/29/2015
<b>SERIAL NUMBER</b>	86170326
<b>MARK SECTION</b>	
<b>MARK</b>	DESCOVY (see, <a href="#">mark</a> )
<b>ATTORNEY INFORMATION (current)</b>	
<b>NAME</b>	Gretchen R. Stroud
<b>ATTORNEY BAR MEMBERSHIP NUMBER</b>	NOT SPECIFIED
<b>YEAR OF ADMISSION</b>	NOT SPECIFIED
<b>U.S. STATE/ COMMONWEALTH/ TERRITORY</b>	NOT SPECIFIED
<b>FIRM NAME</b>	GILEAD SCIENCES INC.
<b>STREET</b>	333 LAKESIDE DR
<b>CITY</b>	FOSTER CITY
<b>STATE</b>	California
<b>POSTAL CODE</b>	94404-1147
<b>COUNTRY/REGION/JURISDICTION/U.S. TERRITORY</b>	United States
<b>PHONE</b>	(650) 522-2401
<b>EMAIL</b>	trademarks@gilead.com
<b>ATTORNEY INFORMATION (proposed)</b>	
<b>NAME</b>	Gretchen R. Stroud
<b>ATTORNEY BAR MEMBERSHIP NUMBER</b>	XXX
<b>YEAR OF ADMISSION</b>	XXXX
<b>U.S. STATE/ COMMONWEALTH/ TERRITORY</b>	XX
<b>FIRM NAME</b>	GILEAD SCIENCES INC.
<b>STREET</b>	333 LAKESIDE DR
<b>CITY</b>	FOSTER CITY
<b>STATE</b>	California
<b>POSTAL CODE</b>	94404-1147
<b>COUNTRY/REGION/JURISDICTION/U.S. TERRITORY</b>	United States
<b>PHONE</b>	(650) 522-2401



FAX	650-522-5575
EMAIL	trademarks@gilead.com
DOCKET/REFERENCE NUMBER	04021
OTHER APPOINTED ATTORNEY	Lori Mayall; Jack Wessel; Shelley Lai; Cynthia Smuzynska
<b>CORRESPONDENCE INFORMATION (current)</b>	
NAME	GRETCHEN R. STROUD
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE	trademarks@gilead.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES)	michelle.jarrell@gilead.com
<b>CORRESPONDENCE INFORMATION (proposed)</b>	
NAME	Gretchen R. Stroud
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE	trademarks@gilead.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES)	TMTTeam@gilead.com
DOCKET/REFERENCE NUMBER	04021
<b>GOODS AND/OR SERVICES SECTION</b>	
INTERNATIONAL CLASS	005
GOODS OR SERVICES TO BE DELETED	hepatitis and anti-inflammatories; anti-fungals; liver diseases and disorders, respiratory diseases and disorders, oncological diseases and disorders, and cardiovascular diseases and disorders
GOODS OR SERVICES IN USE IN COMMERCE	pharmaceutical preparations for the prevention and treatment of HIV infection; antivirals; pharmaceutical preparations for use in the treatment of infectious diseases
SPECIMEN FILE NAME(S)	<a href="\\TICRS\EXPORT18\IMAGEOUT 18\861\703\86170326.xml2\8150002.JPG">\\TICRS\EXPORT18\IMAGEOUT 18\861\703\86170326.xml2\8150002.JPG</a>
SPECIMEN DESCRIPTION	Photograph of registrant's label displaying the mark in use
WEBPAGE URL	None Provided
WEBPAGE DATE OF ACCESS	None Provided
<b>OWNER SECTION (current)</b>	
NAME	Gilead Sciences Ireland UC
MAILING ADDRESS	IDA Business and Technology Park
CITY	Carrigtohill, Co. Cork
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY	Ireland
PHONE	(650) 522-2401
EMAIL	XXXX
<b>OWNER SECTION (proposed)</b>	
NAME	Gilead Sciences Ireland UC
MAILING ADDRESS	IDA Business and Technology Park
CITY	Carrigtohill, Co. Cork

<b>COUNTRY/REGION/JURISDICTION/U.S. TERRITORY</b>	Ireland
<b>PHONE</b>	(650) 522-2401
<b>EMAIL</b>	XXXX
<b>LEGAL ENTITY SECTION (current)</b>	
<b>TYPE</b>	UNLIMITED COMPANY
<b>STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY WHERE LEGALLY ORGANIZED</b>	Ireland
<b>PAYMENT SECTION</b>	
<b>NUMBER OF CLASSES</b>	1
<b>NUMBER OF CLASSES PAID</b>	1
<b>COMBINED §§ 8 &amp; 15 FILING FEE PER CLASS</b>	425
<b>TOTAL FEE PAID</b>	425
<b>SIGNATURE SECTION</b>	
<b>SIGNATURE</b>	/Gretchen R. Stroud/
<b>SIGNATORY'S NAME</b>	Gretchen R. Stroud
<b>SIGNATORY'S POSITION</b>	Attorney of record, California Bar member
<b>DATE SIGNED</b>	01/29/2021
<b>SIGNATORY'S PHONE NUMBER</b>	650-522-2401
<b>SIGNATURE METHOD</b>	Sent to third party for signature
<b>PAYMENT METHOD</b>	DA
<b>FILING INFORMATION</b>	
<b>SUBMIT DATE</b>	Fri Jan 29 17:15:17 ET 2021
<b>TEAS STAMP</b>	USPTO/S08N15-XXX.XXX.XXX. XX-20210129171517664823-4 876632-760e5bf44c8021c273 f7ee6bab59faf529653cf637a 98ad1d65294e1a1da8e9d9c-D A-15166164-20210129162038 170642

## Combined Declaration of Use and Incontestability under Sections 8 & 15

### To the Commissioner for Trademarks:

**REGISTRATION NUMBER:** 4876632

**REGISTRATION DATE:** 12/29/2015

**MARK:** DESCOVY

**Current:** The owner, Gilead Sciences Ireland UC a(n) UNLIMITED COMPANY, legally organized under the laws of Ireland, having an address of

IDA Business and Technology Park  
Carrigtohill, Co. Cork,  
Ireland  
XXXX  
(650) 522-2401

**Proposed:** The owner, Gilead Sciences Ireland UC, UNLIMITED COMPANY legally organized under the laws of Ireland, having an address of

IDA Business and Technology Park  
Carrigtohill, Co. Cork,  
Ireland  
(650) 522-2401  
XXXX

is filing a Combined Declaration of Use and Incontestability under Sections 8 & 15.

For International Class 005, this filing does **NOT** cover the following goods or services for this specific class listed in the registration, and these goods or services are to be permanently **deleted** from the registration: hepatitis and anti-inflammatories; anti-fungals; liver diseases and disorders, respiratory diseases and disorders, oncological diseases and disorders, and cardiovascular diseases and disorders

The mark is in use in commerce on or in connection with the following goods or services listed in the existing registration for this specific class: pharmaceutical preparations for the prevention and treatment of HIV infection; antivirals; pharmaceutical preparations for use in the treatment of infectious diseases

For the remaining goods or services, the mark has been continuously used in commerce for five (5) consecutive years after the date of registration, or the date of publication under Section 12(c), and is still in use in commerce on or in connection with these goods or services. Also, no final decision adverse to the owner's claim of ownership of such mark for those goods or services exists, or to the owner's right to register the same or to keep the same on the register; and, no proceeding involving said rights pending and not disposed of in either the U.S. Patent and Trademark Office or the courts exists.

The owner is submitting one(or more) specimen(s) for this class showing the mark as used in commerce on or in connection with any item in this class, consisting of a(n) Photograph of registrant's label displaying the mark in use.

[Specimen File1](#)

Webpage URL: None Provided

Webpage Date of Access: None Provided

The owner's/holder's current attorney information: Gretchen R. Stroud. Gretchen R. Stroud of GILEAD SCIENCES INC., is located at

333 LAKESIDE DR  
FOSTER CITY, California 94404-1147  
United States

The phone number is (650) 522-2401.

The email address is trademarks@gilead.com

The owner's/holder's proposed attorney information: Gretchen R. Stroud. Other appointed attorneys are Lori Mayall; Jack Wessel; Shelley Lai;

Cynthia Smuzynska. Gretchen R. Stroud of GILEAD SCIENCES INC., is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at

333 LAKESIDE DR  
FOSTER CITY, California 94404-1147  
United States

The docket/reference number is 04021.

The phone number is (650) 522-2401.

The fax number is 650-522-5575.

The email address is trademarks@gilead.com

Gretchen R. Stroud submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

**Correspondence Information (current):**

GRETCHEN R. STROUD  
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gilead.com  
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): michelle.jarrell@gilead.com

**Correspondence Information (proposed):**

Gretchen R. Stroud  
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gilead.com  
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): TMTeam@gilead.com

The docket/reference number is 04021.

**Requirement for Email and Electronic Filing:** I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of \$425 will be submitted with the form, representing payment for 1 class(es), plus any additional grace period fee, if necessary.

**Declaration**

- Unless the owner has specifically claimed excusable nonuse, the mark is in use in commerce on or in connection with the goods/services or to indicate membership in the collective membership organization identified above, as evidenced by the attached specimen(s).
- Unless the owner has specifically claimed excusable nonuse, the specimen(s) shows the mark as currently used in commerce on or in connection with the goods/services/collective membership organization.
- The mark has been in continuous use in commerce for five consecutive years after the date of registration, or the date of publication under 15 U.S.C. § 1062(c), and is still in use in commerce on or in connection with all goods/services, or to indicate membership in the collective membership organization, listed in the existing registration.
- There has been no final decision adverse to the owner's claim of ownership of such mark for such goods/services, or to indicate membership in the collective membership organization, or to the owner's right to register the same or to keep the same on the register.
- There is no proceeding involving said rights pending and not finally disposed of either in the United States Patent and Trademark Office or in a court.
- To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
- The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of this submission and the registration, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Signature: /Gretchen R. Stroud/ Date: 01/29/2021

Signatory's Name: Gretchen R. Stroud

Signatory's Position: Attorney of record, California Bar member

Signatory's Phone: 650-522-2401

Signature method: Sent to third party for signature

**Mailing Address (current):**

GILEAD SCIENCES INC.  
333 LAKESIDE DR  
FOSTER CITY, California 94404-1147

**Mailing Address (proposed):**

GILEAD SCIENCES INC.  
333 LAKESIDE DR  
FOSTER CITY, California 94404-1147

Serial Number: 86170326

Internet Transmission Date: Fri Jan 29 17:15:17 ET 2021

TEAS Stamp: USPTO/S08N15-XXX.XXX.XXX.XX-202101291715

17664823-4876632-760e5bf44c8021c273f7ee6

bab59faf529653cf637a98ad1d65294e1a1da8e9

d9c-DA-15166164-20210129162038170642



NDC 61958-2002-1 30 tablets

**Descovy<sup>®</sup>**  
(emtricitabine and tenofovir  
alafenamide) Tablets

**200 mg/25 mg**

See pharmacist. Do not cover ALERT box with pharmacy label.

**ALERT: Find out about medicines that should NOT be taken with Descovy<sup>®</sup>**

**ROUTING SHEET TO POST REGISTRATION (PRU)**

**Registration Number:** 4876632



**Serial Number:** 86170326



**RAM Sale Number:** 4876632

**RAM Accounting Date:** 20210129

**Total Fees:** \$425

Note: Process in accordance with Post Registration Standard Operating Procedure (SOP)

<u>Transaction</u>	<u>Fee Code</u>	<u>Transaction Date</u>	<u>Fee per Class</u>	<u>Number of Classes</u>	<u>Number of Classes Paid</u>	<u>Total Fee</u>
§8 affidavit	7205	20210129	\$125	1	1	\$125
§15 affidavit	7208	20210129	\$200	1	1	\$200

Physical Location: MADCD- NO PHYSICAL FILE

Lost Case Flag: False

In TICRS (AM-FLG-IN-TICRS): True

**Transaction Date:** 20210129



# EXHIBIT C



For assistance with TSDR, email [teas@uspto.gov](mailto:teas@uspto.gov) and include your serial number, the document you are looking for, and a screenshot of any error messages you have received.

[STATUS](#)   [DOCUMENTS](#)   [MAINTENANCE](#)

[Back to Search](#)

[Print](#)

**Generated on:** This page was generated by TSDR on 2021-04-22 15:58:17 EDT

**Mark:** AJOVY

# AJOVY

**US Serial Number:** 87237174

**Application Filing Date:** Nov. 15, 2016

**US Registration Number:** 5633449

**Registration Date:** Dec. 18, 2018

**Filed as TEAS RF:** Yes

**Currently TEAS RF:** Yes

**Register:** Principal

**Mark Type:** Trademark

**TM5 Common Status**

LIVE/REGISTRATION/Issued and Active

**Descriptor:**



The trademark application has been registered with the Office

**Status:** Registered. The registration date is used to determine when post-registration maintenance documents are due.

**Status Date:** Dec. 18, 2018

**Publication Date:** Apr. 04, 2017

**Notice of Allowance Date:** May 30, 2017

## Mark Information

## Goods and Services

### Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((...)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks \*..\* identify additional (new) wording in the goods/services.

**For:** Pharmaceutical preparations for the treatment of migraines

**International Class(es):** 005 - Primary Class

**U.S Class(es):** 006, 018, 044, 046, 050

**Class Status:** ACTIVE

**Basis:** 1(a)

**First Use:** Sep. 19, 2018

**Use in Commerce:** Sep. 19, 2018

## Basis Information (Case Level)

## Current Owner(s) Information

**Owner Name:** TEVA PHARMACEUTICALS INTERNATIONAL GMBH

[Privacy](#) - [Terms](#)

**Owner Address:** SCHLÜSSELSTRASSE 12  
8645 JONA SWITZERLAND

**Legal Entity Type:** GESELLSCHAFT MIT BESCHRÄNKTER  
HAFTUNG (GMBH)

**State or Country Where Organized:** SWITZERLAND

**[Attorney/Correspondence Information](#)**

**[Prosecution History](#)**

**[TM Staff and Location Information](#)**

**[Assignment Abstract Of Title Information - Click to Load](#)**

**[Proceedings - Click to Load](#)**

For assistance with TSDR, email [teas@uspto.gov](mailto:teas@uspto.gov) and include your serial number, the document you are looking for, and a screenshot of any error messages you have received.

[STATUS](#)   [DOCUMENTS](#)   [MAINTENANCE](#)

[Back to Search](#)

[Print](#)

**Generated on:** This page was generated by TSDR on 2021-04-22 15:54:31 EDT

**Mark:** DESCOVY

# DESCOVY

**US Serial Number:** 86170326

**Application Filing Date:** Jan. 20, 2014

**US Registration Number:** 4876632

**Registration Date:** Dec. 29, 2015

**Register:** Principal

**Mark Type:** Trademark

**TM5 Common Status**

LIVE/REGISTRATION/Issued and Active

**Descriptor:**



The trademark application has been registered with the Office

**Status:** Registered. The registration date is used to determine when post-registration maintenance documents are due.

**Status Date:** Dec. 29, 2015

**Publication Date:** Sep. 30, 2014

## Mark Information

## Foreign Information

## Goods and Services

### Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((.)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks \*..\* identify additional (new) wording in the goods/services.

**For:** pharmaceutical preparations for the prevention and treatment of hepatitis and HIV infection; antivirals; anti-infective pharmaceutical preparations for use in the treatment of infectious diseases, liver diseases and disorders, respiratory diseases and disorders, oncological diseases and disorders, and cardiovascular diseases and disorders

**International Class(es):** 005 - Primary Class

**U.S Class(es):** 006, 018, 044, 046, 050

**Class Status:** ACTIVE

**Basis:** 44(e)

## Basis Information (Case Level)

## Current Owner(s) Information

[Privacy](#) - [Terms](#)

**Owner Name:** Gilead Sciences Ireland UC

**Owner Address:** IDA Business and Technology Park  
Carrigtohill, Co. Cork IRELAND

**Legal Entity Type:** UNLIMITED COMPANY

**State or Country Where  
Organized:** IRELAND

### [Attorney/Correspondence Information](#)

### [Prosecution History](#)

### [TM Staff and Location Information](#)

### [Assignment Abstract Of Title Information - Click to Load](#)

### [Proceedings - Click to Load](#)

For assistance with TSDR, email [teas@uspto.gov](mailto:teas@uspto.gov) and include your serial number, the document you are looking for, and a screenshot of any error messages you have received.

**STATUS**      **DOCUMENTS**

[Back to Search](#)

Print

**Generated on:** This page was generated by TSDR on 2021-04-22 15:49:03 EDT

**Mark:** IXOVY

# IXOVY

**US Serial Number:** 90073531

**Application Filing Date:** Jul. 25, 2020

**Register:** Principal

**Mark Type:** Trademark

**TM5 Common Status**

**Descriptor:**



LIVE/APPLICATION/Published for Opposition

A pending trademark application has been examined by the USPTO and has been published in a way that provides an opportunity for the registration.

**Status:** Notice of Allowance (NOA) sent (issued) to the applicant. Applicant must file a Statement of Use or Extension of Use by the first anniversary of the NOA issuance date.

**Status Date:** Feb. 16, 2021

**Publication Date:** Dec. 22, 2020

**Notice of Allowance Date:** Feb. 16, 2021

## Mark Information

## Goods and Services

### Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((...)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks \*.\* identify additional (new) wording in the goods/services.

**For:** Vaccines

**International Class(es):** 005 - Primary Class

**U.S Class(es):** 006, 018, 044, 046, 050

**Class Status:** ACTIVE

**Basis:** 1(b)

## Basis Information (Case Level)

## Current Owner(s) Information

**Owner Name:** Novavax, Inc.

**Owner Address:** 21 Firstfield Road  
Gaithersburg, MARYLAND UNITED STATES 20878

[Privacy](#) - [Terms](#)

**Legal Entity Type:** CORPORATION

**State or Country Where Organized:** DELAWARE

[Attorney/Correspondence Information](#)

[Prosecution History](#)

[TM Staff and Location Information](#)

[Assignment Abstract Of Title Information - Click to Load](#)

[Proceedings - Click to Load](#)

For assistance with TSDR, email [teas@uspto.gov](mailto:teas@uspto.gov) and include your serial number, the document you are looking for, and a screenshot of any error messages you have received.

[STATUS](#)   [DOCUMENTS](#)   [MAINTENANCE](#)

[Back to Search](#)

[Print](#)

**Generated on:** This page was generated by TSDR on 2021-04-22 16:00:19 EDT

**Mark:** MELOVY

# MELOVY

**US Serial Number:** 86227110

**Application Filing Date:** Mar. 20, 2014

**US Registration Number:** 4771307

**Registration Date:** Jul. 14, 2015

**Register:** Principal

**Mark Type:** Trademark

**TM5 Common Status**

LIVE/REGISTRATION/Issued and Active

**Descriptor:**



The trademark application has been registered with the Office

**Status:** Registered. The registration date is used to determine when post-registration maintenance documents are due.

**Status Date:** Jul. 14, 2015

**Publication Date:** Oct. 21, 2014

## Mark Information

## Foreign Information

## Goods and Services

### Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((.)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks \*..\* identify additional (new) wording in the goods/services.

**For:** Pharmaceuticals, namely, pharmaceutical preparations for the treatment of viral infections; pharmaceutical preparations for the treatment of cardiovascular disorders and conditions; pharmaceutical preparations for the treatment of respiratory disorders; pharmaceutical preparations for the treatment of fungal diseases and disorders; pharmaceutical preparations for the treatment of infectious disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of HIV/AIDS and hepatitis

**International Class(es):** 005 - Primary Class

**U.S Class(es):** 006, 018, 044, 046, 050

**Class Status:** ACTIVE

**Basis:** 44(e)

## Basis Information (Case Level)

[Privacy](#) - [Terms](#)

## Current Owner(s) Information

**Owner Name:** Gilead Sciences Ireland UC

**DBA, AKA, Formerly:** DBA Gilead Sciences Ireland UC

**Owner Address:** IDA Business and Technology Park  
Carrigtohill, Co. Cork IRELAND

**Legal Entity Type:** Unlimited Company

**State or Country Where  
Organized:** IRELAND

## Attorney/Correspondence Information

### Prosecution History

### TM Staff and Location Information

### Assignment Abstract Of Title Information - [Click to Load](#)

### Proceedings - [Click to Load](#)



For assistance with TSDR, email [teas@uspto.gov](mailto:teas@uspto.gov) and include your serial number, the document you are looking for, and a screenshot of any error messages you have received.

**STATUS**      **DOCUMENTS**

[Back to Search](#)

[Print](#)

**Generated on:** This page was generated by TSDR on 2021-04-22 15:57:00 EDT

**Mark:** RULDOVY

# RULDOVY

**US Serial Number:** 88182285

**Application Filing Date:** Nov. 05, 2018

**Filed as TEAS RF:** Yes


**Currently TEAS RF:** Yes

**Register:** Principal

**Mark Type:** Trademark

**TM5 Common Status**

**Descriptor:**



LIVE/APPLICATION/Under Examination

The trademark application has been accepted by the Office (minimum filing requirements) and that this application has been accepted by the examiner.

**Status:** A second request for extension of time to file a Statement of Use has been granted.

**Status Date:** Oct. 29, 2020

**Publication Date:** Sep. 10, 2019

**Notice of Allowance Date:** Nov. 05, 2019

## Mark Information

## Goods and Services

### Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks \*.\* identify additional (new) wording in the goods/services.

**For:** Pharmaceutical preparations for treatment of oncologic, inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the bone marrow, nervous system, immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microphthalmia, pemphigus vulgaris (PV), multiple sclerosis (MS), and stem cell transplantation

**International Class(es):** 005 - Primary Class

**U.S Class(es):** 006, 018, 044, 046, 050

**Class Status:** ACTIVE

**Basis:** 1(b)

## Basis Information (Case Level)

## Current Owner(s) Information

[Privacy](#) - [Terms](#)

**Owner Name:** Amgen Inc.

**Owner Address:** Trademark Operations - MS-28-5A  
One Amgen Center Drive  
Thousand Oaks, CALIFORNIA UNITED STATES 913201799

**Legal Entity Type:** CORPORATION

**State or Country Where  
Organized:** DELAWARE

### [Attorney/Correspondence Information](#)


### [Prosecution History](#)

### [TM Staff and Location Information](#)

### [Assignment Abstract Of Title Information - Click to Load](#)

### [Proceedings - Click to Load](#)

# EXHIBIT D



[About Us](#)

[R & D](#)

[Media](#)

[Investors](#)

[Career](#)

[Contact Us](#)

[繁體中文](#)

[HOME](#)



Media

[Press Release](#)

[Media Library](#)

## Press Release

[Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg](#)

Taipei, Taiwan, July 27, 2020 – Foresee Pharmaceuticals Co., Ltd. (6576.TWO) (“Foresee”), announced today that it has submitted to the U.S. Food and Drug Administration a 505(b)(2) New Drug Application for CAMCEVI™ 42MG (FP-001 LMIS 50mg), a ready-to-use 6-month depot formulation of leuprolide mesylate. The application seeks approval for the use of this product for the palliative treatment of advanced prostate cancer.

This NDA submission is supported by a previously communicated successful Phase 3 study in 137 Advanced Prostate Carcinoma patients, where treatment with LMIS 50 mg injection every 6 months was demonstrated to be effective, safe and well tolerated.

“In the NDA submission in 2019, FDA suggested that additional device design verification data on the combination product be provided. Since then, with tireless efforts and commitment from the Foresee team and collaborators, as well as continued support of our investors, we have undertaken diligent preparation for the requested information,” said Dr. Ben Chien, Founder and Chairman of Foresee. “We are confident in the resubmission of the NDA.”

“Next step for the FP-001 franchise will be to establish a strong commercial partnership in the US and to prepare for the NDA submission of the 3-month depot of CAMCEVI. We look forward to the successful launch of the FP-001 franchise, providing patients with its differentiated ready-to-use profile.” said Dr. Ben Chien.

"Next step for the FP-001 franchise will be to establish a strong commercial partnership in the US and to prepare for the NDA submission of the 3-month depot of CAMCEVI. We look forward to the successful launch of the FP-001 franchise, providing patients with its differentiated ready-to-use profile." said Dr. Ben Chien.

#### About Foresee Pharmaceuticals Co., Ltd.

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee's R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, secondly its transformative preclinical and clinical first-in-class NCE programs targeting disease areas with high unmet needs.

Foresee's product portfolio includes late stage and early stage programs such as FP-001, 6-month and 3-month, stable, ready-to-use versions of leuprolide mesylate for injection, for which regulatory submissions are planned since 2020; FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in a Phase 2 proof-of-concept study, and target to initiate Phase 2 study for COVID-19 virus induced acute respiratory distress syndrome (ARDS); FP-045, a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia, a mitochondrial-mediated disease; and FP-004, a novel, subcutaneously injectable product in development for the treatment of opioid use disorder and pain.

#### For more information:

##### *Business Development Enquiries:*

Mathieu Boudreau, Ph.D.  
Vice President, Business Development  
[mathieu.boudreau@foreseepharma.com](mailto:mathieu.boudreau@foreseepharma.com)

##### *Public Relations & Investor Relations:*

An Chung  
Public relations/Investor Relations  
[an.chung@foreseepharma.com](mailto:an.chung@foreseepharma.com)

**Foresee Pharmaceuticals Co., Ltd.**

Copyright © 2020 Foresee Pharmaceuticals Co., Ltd. All rights reserved.

